The solubility of Carvedilol, a poorly water-soluble drug widely used in cardiovascular disorders, presents a significant challenge in achieving optimal therapeutic efficacy. This research aimed to enhance the solubility and dissolution rate of Carvedilol through the application of the liquisolid compact technique. Liquisolid compacts were formulated by preparing a drug solution of Carvedilol in PEG with polysorbate 80 as the non-volatile solvent. Microcrystalline cellulose was selected as the carrier powder, while Aerosil served as the coating material. Various ratios of drug solution to carrier powder were investigated to optimize the formulation. The liquisolid compacts were compressed into tablets using a direct compression method. Characterization studies were performed to assess the physical properties and compatibility of the liquisolid compacts. Evaluation parameters included flow properties, compressibility, and compatibility studies using Fourier-transform infrared spectroscopy (FTIR). In vitro dissolution studies were conducted to determine the drug release profile for compact and tablet dosage forms. The results indicated that the liquisolid compacts exhibited good flow properties and compressibility, facilitating tablet formation. FTIR analysis revealed no significant interactions between Carvedilol and the excipients used. The enhanced solubility and dissolution rate of Carvedilol achieved through the liquisolid compact technique can potentially lead to improved bioavailability and therapeutic effectiveness. The increased surface area and improved wetting properties of the liquisolid compacts contributed to enhanced drug dissolution. These findings highlight the potential of the liquisolid compact technique as a promising approach for enhancing the solubility of poorly water-soluble drugs like Carvedilol.